Latest Capital Raises News

Midas Minerals has secured a crucial licence transfer for its Otavi Copper Project acquisition in Namibia, moving closer to drilling plans slated for late 2025. The company now awaits final regulatory approval and capital raising to complete the deal.

Biotron Limited reported a significantly reduced net loss of $318,572 for FY2025, bolstered by a $1.27 million capital raise and a $1.81 million R&D tax rebate, as it advances clinical and preclinical antiviral programs.

Gryphon Capital Income Trust (ASX, GCI) reported a robust fiscal 2025 with a 41.65% jump in revenue and a substantial capital raise to expand its RMBS/ABS portfolio. The Trust’s net assets topped $1 billion, reflecting strong investor confidence and strategic growth.

Flight Centre Travel Group has launched a A$450 million convertible notes offering due 2032, aiming to repurchase up to A$325 million of existing notes and support its growth ambitions with extended debt maturity.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Enlitic, Inc. reported a sharp revenue increase driven by migration services and subscription growth, while sustaining a net loss of US$6.86 million in H1 2025. The company secured a binding MOU with GE Healthcare and completed a A$10 million capital raise.

BPH Energy Limited reported a 49% increase in net profit for FY2025, driven by gains in its energy and biotech investments, while facing a pivotal Federal Court hearing over the renewal of the PEP-11 offshore gas exploration permit.

Savannah Goldfields Limited has announced a $15 million equity raising through a placement and conditional placement, offering free attaching options subject to shareholder approval. The capital raise aims to strengthen the company’s financial position and support its operational restart plans.

Nova Eye Medical Limited reported a 25% increase in revenue to AUD 29.3 million for FY2025, driven by strong sales in its glaucoma surgical devices segment, yet posted a net loss after tax of AUD 9.1 million. The company raised AUD 6.2 million through a share placement to support growth initiatives.

Infragreen Group Limited has reported a robust FY25 performance, with pro forma revenue and EBITDA significantly exceeding forecasts, supported by a successful $40 million IPO.

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.